Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H16Cl2N4 |
| Molecular Weight | 395.285 |
| Optical Activity | ( + ) |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=C(Cl)C=C(C=C1)[C@@H]2CNCC3=C2C=CC(=C3)C4=CN5N=CN=C5C=C4
InChI
InChIKey=VXVOMCCQHIVMJK-SFHVURJKSA-N
InChI=1S/C21H16Cl2N4/c22-19-5-2-14(8-20(19)23)18-10-24-9-16-7-13(1-4-17(16)18)15-3-6-21-25-12-26-27(21)11-15/h1-8,11-12,18,24H,9-10H2/t18-/m0/s1
| Molecular Formula | C21H16Cl2N4 |
| Molecular Weight | 395.285 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:36:42 GMT 2023
by
admin
on
Sat Dec 16 11:36:42 GMT 2023
|
| Record UNII |
92R6N6C82N
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
92R6N6C82N
Created by
admin on Sat Dec 16 11:36:42 GMT 2023 , Edited by admin on Sat Dec 16 11:36:42 GMT 2023
|
PRIMARY | |||
|
49765785
Created by
admin on Sat Dec 16 11:36:42 GMT 2023 , Edited by admin on Sat Dec 16 11:36:42 GMT 2023
|
PRIMARY | |||
|
BMS-866949
Created by
admin on Sat Dec 16 11:36:42 GMT 2023 , Edited by admin on Sat Dec 16 11:36:42 GMT 2023
|
PRIMARY | Official Title: Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-866949 in Healthy SubjectsPurpose: The purpose of this study is to evaluate the safety profile, tolerability, pharmacokinetics and pharmacodynamics of ascending single doses of BMS-866949 in healthy subjects. | ||
|
1254941-82-6
Created by
admin on Sat Dec 16 11:36:42 GMT 2023 , Edited by admin on Sat Dec 16 11:36:42 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: AMRI; Class: Antidepressant; Mechanism of Action: Biogenic amine uptake inhibitor; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phase: Phase I for Major depressive disorder; Most Recent Events: 26 Mar 2012 Bristol-Myers Squibb terminates a phase I trial in volunteers in Sweden (NCT01124344), 31 Jul 2009 Phase-I clinical trials in Major depressive disorder in Sweden (PO)
|
